首页> 美国卫生研究院文献>Acta Bio Medica : Atenei Parmensis >Abincol® (Lactobacillus plantarum LP01 Lactobacillus lactis subspecies cremoris LLC02 Lactobacillus delbrueckii LDD01) an oral nutraceutical pragmatic use in patients with chronic intestinal disorders
【2h】

Abincol® (Lactobacillus plantarum LP01 Lactobacillus lactis subspecies cremoris LLC02 Lactobacillus delbrueckii LDD01) an oral nutraceutical pragmatic use in patients with chronic intestinal disorders

机译:Abincol®(植物乳杆菌LP01乳酸乳杆菌亚种cremoris LLC02德氏乳杆菌LDD01)用于慢性肠道疾病患者的口服营养保健品

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Chronic intestinal disorders (CID), including inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn’s disease, irritable bowel syndrome (IBS), and diverticular disease (DD), are diseases that relapse episodes. There is evidence that patients with CID have intestinal dysbiosis, so probiotics may counterbalance the impaired microbiota. Therefore, the current survey evaluated the efficacy and safety of Abincol®,an oral nutraceuticalcontaining a probiotic mixture with LP01 (1 billion of living cells), LLC02 (800 millions of living cells), and LDD01 (200 millions of living cells), in 3,460 outpatients (1,660 males and 1,800 females, mean age 55 years) with chronic intestinal disorders. Patients took 1 stick/daily for 8 weeks. Abincol® significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol® may be considered an effective and safe therapeutic option in the management of patients with chronic intestinal disorders. ( )
机译:慢性肠道疾病(CID),包括炎症性肠病(IBD),例如溃疡性结肠炎和克罗恩病,肠易激综合症(IBS)和憩室病(DD),都是复发性疾病。有证据表明,患有CID的患者患有肠道营养不良,因此益生菌可以抵消受损的微生物群。因此,本次调查评估了含有益生菌混合物与LP01(10亿个活细胞),LLC02(8亿个活细胞)和LDD01(2亿个活细胞)的益生菌混合物的口服保健食品Abincol®的功效和安全性。 3,460名患有慢性肠道疾病的门诊病人(男性1,660位,女性1,800位,平均年龄55岁)。患者每天服用1支棍子,持续8周。 Abincol®显着减少了肠道症状的出现和严重程度,并改善了粪便形式。总而言之,当前调查表明Abincol®可被视为治疗慢性肠道疾病患者的一种有效且安全的治疗选择。 ()

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号